ATE222124T1 - Chemische mittel - Google Patents

Chemische mittel

Info

Publication number
ATE222124T1
ATE222124T1 AT95941214T AT95941214T ATE222124T1 AT E222124 T1 ATE222124 T1 AT E222124T1 AT 95941214 T AT95941214 T AT 95941214T AT 95941214 T AT95941214 T AT 95941214T AT E222124 T1 ATE222124 T1 AT E222124T1
Authority
AT
Austria
Prior art keywords
enzyme
host
prodrug
component
natural
Prior art date
Application number
AT95941214T
Other languages
English (en)
Inventor
Christopher Taylorson
Hendrikus Johannes Eggelte
Antonio Tarragona-Fiol
Brian Robert Rabin
Francis Thomas Boyle
Park Alderley
John Frederick Hennam
David Charles Blakey
Peter Robert Marsham
David William Heaton
David Huw Davies
Anthony Michael Slater
Laurent Francois Hennequin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE222124(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9426192.2A external-priority patent/GB9426192D0/en
Priority claimed from GBGB9516810.0A external-priority patent/GB9516810D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE222124T1 publication Critical patent/ATE222124T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • External Artificial Organs (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Saccharide Compounds (AREA)
AT95941214T 1994-12-23 1995-12-21 Chemische mittel ATE222124T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9426192.2A GB9426192D0 (en) 1994-12-23 1994-12-23 Chemical compounds
GBGB9516810.0A GB9516810D0 (en) 1995-08-16 1995-08-16 Chemical compounds
PCT/GB1995/002991 WO1996020011A1 (en) 1994-12-23 1995-12-21 Chemical compounds

Publications (1)

Publication Number Publication Date
ATE222124T1 true ATE222124T1 (de) 2002-08-15

Family

ID=26306259

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95941214T ATE222124T1 (de) 1994-12-23 1995-12-21 Chemische mittel

Country Status (23)

Country Link
US (1) US5985281A (de)
EP (1) EP0806964B1 (de)
JP (1) JP3805365B2 (de)
KR (1) KR100270650B1 (de)
CN (1) CN1095677C (de)
AT (1) ATE222124T1 (de)
AU (1) AU701916B2 (de)
BR (1) BR9510490B1 (de)
CA (1) CA2205091A1 (de)
CZ (1) CZ195297A3 (de)
DE (1) DE69527805T2 (de)
ES (1) ES2181805T3 (de)
FI (1) FI972683A0 (de)
HU (1) HUT77450A (de)
IL (1) IL116511A0 (de)
MX (1) MX9704575A (de)
NO (1) NO972882L (de)
NZ (1) NZ297529A (de)
PL (1) PL184031B1 (de)
RU (1) RU2189251C2 (de)
SK (1) SK80997A3 (de)
TR (1) TR199501654A2 (de)
WO (1) WO1996020011A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0844885A2 (de) * 1995-08-16 1998-06-03 Zeneca Limited Chemische verbindungen
SG71046A1 (en) 1996-10-10 2000-03-21 Connector Systems Tech Nv High density connector and method of manufacture
WO1998035988A1 (en) * 1997-02-14 1998-08-20 Zeneca Limited Proteins
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
EP1113819B1 (de) * 1998-09-18 2011-02-23 Immunomedics, Inc. Antikörper verwiesene enzymprodrugtherapie mit glukuronidase
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US20040117863A1 (en) * 1998-09-18 2004-06-17 Edge Michael D. Transgenically produced fusion proteins
CN1414970A (zh) * 1999-09-17 2003-04-30 Gtc生物治疗学公司 以转基因方式生产的融合蛋白
BR0207297A (pt) 2001-02-15 2005-04-19 King Pharmaceuticals Inc Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
BR0316643A (pt) * 2002-11-27 2005-10-11 Gtc Biotherapeutics Inc Anticorpos modificados estavelmente produzidos no leite e método de produzir os mesmos
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
JP5328019B2 (ja) * 2005-10-21 2013-10-30 レヴォ バイオロジクス インコーポレイテッド 抗体依存性細胞障害活性を増強させた抗体、その調製法および使用法
WO2007149827A2 (en) * 2006-06-20 2007-12-27 Janssen Pharmaceutica, N.V. Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
US20080031866A1 (en) * 2006-06-20 2008-02-07 Eichenbaum Gary M Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
EP2077991B1 (de) 2006-10-03 2014-02-26 Techfields Biochem Co. Ltd Positiv geladene, wasserlösliche prodrugs von losten und verwandten verbindungen mit sehr hohen hautpenetrationsraten
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
EP2279003A4 (de) * 2008-05-01 2013-04-03 Gtc Biotherapeutics Inc Anti-cd137-antikörper als mittel zur behandlung von entzündlichen erkrankungen
US10745492B1 (en) 2019-04-03 2020-08-18 Ark Diagnostics, Inc. Antibodies to symmetrically dimethylated arginine analytes and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5433955A (en) * 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
ES2075893T3 (es) * 1989-01-23 1995-10-16 Akzo Nobel Nv Activacion in vivo especifica de sede de farmacos terapeuticos.
WO1993015208A1 (en) * 1992-01-30 1993-08-05 Genzyme Limited Chiral synthesis with modified enzymes
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5389537A (en) * 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity

Also Published As

Publication number Publication date
AU4269796A (en) 1996-07-19
KR100270650B1 (ko) 2000-11-01
PL320964A1 (en) 1997-11-24
CZ195297A3 (en) 1997-12-17
RU2189251C2 (ru) 2002-09-20
FI972683L (fi) 1997-06-19
AU701916B2 (en) 1999-02-11
BR9510490B1 (pt) 2010-10-05
MX9704575A (es) 1997-10-31
JPH10511547A (ja) 1998-11-10
BR9510490A (pt) 1998-01-13
US5985281A (en) 1999-11-16
TR199501654A2 (tr) 1996-07-21
SK80997A3 (en) 1998-02-04
EP0806964B1 (de) 2002-08-14
CN1095677C (zh) 2002-12-11
FI972683A7 (fi) 1997-06-19
DE69527805D1 (de) 2002-09-19
CA2205091A1 (en) 1996-07-04
ES2181805T3 (es) 2003-03-01
PL184031B1 (pl) 2002-08-30
JP3805365B2 (ja) 2006-08-02
IL116511A0 (en) 1996-07-23
WO1996020011A1 (en) 1996-07-04
NO972882L (no) 1997-08-19
FI972683A0 (fi) 1997-06-19
NO972882D0 (no) 1997-06-20
EP0806964A1 (de) 1997-11-19
CN1171054A (zh) 1998-01-21
NZ297529A (en) 1999-07-29
TR199501654A3 (de) 1996-07-21
HUT77450A (hu) 1998-04-28
DE69527805T2 (de) 2003-04-24

Similar Documents

Publication Publication Date Title
ATE222124T1 (de) Chemische mittel
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
DE69329735D1 (de) Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken
BR0210225A (pt) Holotoxina do cólera imunogênica mutante, composição imunogênica, método para realçar a resposta imune de um hospedeiro vertebrado a um antìgeno, sequência de dna isolada e purificada, molécula de ácido nucleico, célula hospedeira, método para produzir uma holotoxina do cólera imunogênica mutante, e, uso de uma holotoxina do cólera mutante
CY1106602T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
NO20014415L (no) Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
ATE297762T1 (de) Peg-lhrh analog konjugate
FI953529A0 (fi) Rokotteita, jotka sisältävät gangliosidi-KLH-konjugaattia ja QS-21-ainetta
BR0209254A (pt) anticorpos de bloqueio cripto e usos dos mesmos
PT1323346E (pt) Administracao transepitelial de antigenicos com a finalidade de provocar tolerancia e imunidade
BRPI0010612B8 (pt) vacinas
DE69932733D1 (de) Photosensitizer-konjugate zur zielrichtung von intrazellulare pathogene
EP0859625A4 (de) Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
MX9102101A (es) Composiciones que contienen psyllium. composiciones que contienen psyllium.
BR0313048A (pt) Uso de alquilfosfocolinas em combinação com medicamentos antitumorais
DK1161250T3 (da) Immunstimulerende bakteriemembranfraktioner i cancerbehandling
AU6182994A (en) Bifunctional glycoproteins having a modified carbohydrate complement, and their use in tumor-selective therapy
ATE310750T1 (de) Verotoxin b untereinheit zur immunisierunug
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
DE59712247D1 (de) Mammakarzinom-assoziiertes gen
IT1274592B (it) Composizione farmaceutica per la terapia tumorale contenente xenoantigeni
WO2003032895A3 (en) Methods and pharmaceutical compositions for stimulating the immune system and/or treating cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties